RadNet (RadNet) 12-1 Month Momentum % : 77.09% (As of Apr. 27, 2024)

View and export this data going back to 1997. Start your Free Trial

What is RadNet 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-27), RadNet's 12-1 Month Momentum % is 77.09%.

The industry rank for RadNet's 12-1 Month Momentum % or its related term are showing as below:

RDNT's 12-1 Month Momentum % is ranked better than
93.25% of 237 companies
in the Medical Diagnostics & Research industry
Industry Median: -18.51 vs RDNT: 77.09

Competitive Comparison of RadNet's 12-1 Month Momentum %

For the Diagnostics & Research subindustry, RadNet's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RadNet's 12-1 Month Momentum % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, RadNet's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where RadNet's 12-1 Month Momentum % falls into.

RadNet (NAS:RDNT) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RadNet (NAS:RDNT) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

RadNet 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of RadNet's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

RadNet (RadNet) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » RadNet Inc (NAS:RDNT) » Definitions » 12-1 Month Momentum %

Comparable Companies

NEOG SHC GH NEO TWST MYGN VCYT OPK LAB FLGT TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN

Traded in Other Exchanges

PQIA:Germany

Address

1510 Cotner Avenue, Los Angeles, CA, USA, 90025

Website

http://www.radnet.com

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.

Executives

Michael N Murdock	officer: Executive Vice President	3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 752012776
Christine Nayoma Gordon	director	3081 PANAMA AVE., CARMICHAEL CA 95608
Gregory Sorensen	director, officer: EVP Chief Science Officer	C/O DFB HEALTHCARE ACQUISITIONS CORP, 780 THIRD AVENUE, NEW YORK NY 10017
Norman R Hames	director, officer: Vice President
Stephen M Forthuber	officer: Executive Vice President	3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 75201-2776
Ruth Louisa Villigerwilson	director, officer: Senior Vice President	3700 WALNUT AVENUE, LONG BEACH CA 90801
David L Swartz	director	1510 COTNER AVENUE, LOS ANGELES CA 90025
Gregory E. Spurlock	director	4116 E. NORTHRIDGE CIRCLE, MESA AZ 85215-9807
John V Crues	director	1510 COTNER AVE, LOS ANGELES CA 90025
Lawrence L Levitt	director	2934 1/2 BEVERLY GLEN CIRCLE #325, LOS ANGELES CA 90077
Ranjan Jayanathan	officer: Chief Information Officer	13388 HUNT RIDGE ROAD, ELLICOTT CITY MD 21042
Laura Pastre Jacobs	director	10154 BRIDLEVALE DRIVE, LOS ANGELES CA 90064
Karen B. Kaplan Survivor's Trust	other: Indirect owner	10776 WILSHIRE BLVD/, LOS ANGELES CA 90024-6447
David Jeffrey Katz	officer: EVP and General Counsel	1510 COTNER AVE, LOS ANGELES CA 90025
Sherman Michael L Md	director